Malignant Tumor Clinical Trial
Official title:
A Prospective, Open Label, One Arm Study for a Compassionate Use of Diffusing Alpha Radiation Therapy
NCT number | NCT05781555 |
Other study ID # | CTP- ALL-00 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | March 22, 2023 |
Est. completion date | April 2025 |
This study is a Compassionate clinical study for the treatment of Malignant Tumors. The primary endpoint of the study is to assess the frequency, severity and causality of acute adverse events related to the DaRT treatment. Adverse events will be assessed and graded according to Common Terminology and Criteria for Adverse Events (CTCAE) version 5.0. The secondary endpoint is to assess the tumor response to DaRT treatment assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1) 3 months after DaRT seed insertion.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | April 2025 |
Est. primary completion date | April 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subjects with any malignancy - Subjects with a tumor size = 7 centimeters in the longest diameter - Subjects over 18 years old - Subjects' life expectancy is more than 6 months - Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test and are required to use an acceptable contraceptive method to prevent pregnancy for 3 months after treatment. - Subjects/Surrogate decision maker are willing to sign an informed consent form Exclusion Criteria: - Known hypersensitivity to any of the components of the treatment. - Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in the last 12 months. - Any medical or psychiatric illness which in the opinion of the investigator would compromise the patient's ability to tolerate this treatment or interfere with the study endpoints. - Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT. - Patients must agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy. - High probability of protocol non-compliance (in opinion of investigator). - Subjects/Surrogate decision maker not willing to sign an informed consent. - Women who are pregnant or breastfeeding. |
Country | Name | City | State |
---|---|---|---|
Israel | Hadassah Ein Kerem | Jerusalem |
Lead Sponsor | Collaborator |
---|---|
Alpha Tau Medical LTD. |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To assess the frequency, severity and causality of acute adverse events. | The primary endpoint of the study is to assess the frequency, severity and causality of acute adverse events related to the DaRT treatment. Adverse events will be assessed and graded according to Common Terminology and Criteria for Adverse Events (CTCAE) version 5.0. | From Day 0 (DaRT insertion ) | |
Secondary | To assess the tumor response to DaRT treatment | The secondary endpoint is to assess the tumor response to DaRT treatment assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1) | 3 months after DaRT seed insertion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04691349 -
CAR-T for r/r Malignant Tumors in Children
|
Early Phase 1 | |
Recruiting |
NCT04672473 -
Treatment of Malignant Tumors With Antigen Peptide-specific DC-CTL Cells and Decitabine
|
Phase 1/Phase 2 | |
Recruiting |
NCT06080984 -
The Application of Novel Oncolytic Virus in Late Stage Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04991506 -
A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT02552004 -
Assessment of Intraoperative Probe-based Confocal Laser Endomicroscopy in Digestive and Endocrine Surgery: a Pilot Study
|
N/A | |
Recruiting |
NCT05280873 -
Pirfenidone Combined With Methylprednisolone Versus Methylprednisolone in the Treatment of CIP
|
Phase 1 | |
Completed |
NCT06093945 -
Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT05592262 -
Pharmacokinetic Test of High-fat Diet After Oral Administration of SHR2554 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03012945 -
Epidural Anesthesia-analgesia and Long-term Outcome
|
N/A | |
Recruiting |
NCT04686682 -
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06084767 -
68Ga-TCR-FAPI PET/CT in Patients With Various Types of Cancer
|
N/A | |
Enrolling by invitation |
NCT02937246 -
Efficacy of Partial Covered Double Bare Metal Stent Compared to Uncovered Double Bare Metal Stent in Malignant Biliary Obstruction
|
N/A | |
Completed |
NCT03354741 -
Stimulation of Acupuncture Points by Athermic Laser Therapy for the Prevention of Chemotherapy Induced Nausea and Vomiting in Children
|
N/A | |
Recruiting |
NCT03931720 -
Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor
|
Phase 1/Phase 2 | |
Completed |
NCT01906632 -
Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy
|
N/A | |
Recruiting |
NCT05596344 -
Long-term Follow-up of Anxiety and Depression in Patients With Malignant Tumors
|
||
Active, not recruiting |
NCT04230200 -
Prospective Screening Programme for Malignant Tumors
|
||
Completed |
NCT04730843 -
A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04952766 -
Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
|
Phase 4 | |
Completed |
NCT01884168 -
Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy
|